Antibody Responses after SARS-CoV-2 Vaccination in Patients with Liver Diseases

The novel mRNA-based vaccines against SARS-CoV-2 display encouraging safety and efficacy profiles. However, there is a paucity of data regarding their immunogenicity and safety in patients with liver diseases (PWLD), especially in those with cirrhosis. We prospectively assessed anti-SARS-CoV-2 S-spi...

Descripción completa

Detalles Bibliográficos
Autores principales: Bakasis, Athanasios-Dimitrios, Bitzogli, Kleopatra, Mouziouras, Dimitrios, Pouliakis, Abraham, Roumpoutsou, Maria, Goules, Andreas V., Androutsakos, Theodoros
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8876976/
https://www.ncbi.nlm.nih.gov/pubmed/35215801
http://dx.doi.org/10.3390/v14020207

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8876976/
https://www.ncbi.nlm.nih.gov/pubmed/35215801
http://dx.doi.org/10.3390/v14020207

Ejemplares similares